Planned
There are currently no planned studies in our center.
Ongoing
StrateGIST-3 (GSK300383)
A Phase 3 Randomized Multicenter Open-Label Study of IDRX-42 versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
- Principal investigator : Prof. Dr. Patrick Schöffski
- Sponsor : GSK
- More information : NCT07218926
- Indication :
- Internal reference number : s71062